Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda has filed a marketing authorization application (MAA) with the European regulatory authorities for Acnex (clindamycin with tretinoin) as treatment for mild to severe acne vulgaris.
Subscribe to our email newsletter
The company’s MAA includes 29 countries using a decentralised procedure (DCP).
Registration in Russia, Turkey and the CIS countries will follow.
Meda CEO Anders Lonner said Acnex is a well documented product that is very effective and well tolerated and will strengthen Meda’s European position in dermatology.